Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

<div>Median PFS and OS in patients who underwent combination of aTACE and apatinib therapy. (a) Median PFS was 10.2 months (95% CI: 8.543–11.857 months) in all subjects. (b) Median OS was 23.300 months (95% CI: 20.833–25.767 months). PFS, progression-free survival; OS, overall survival.</div>

Canadian Journal of Gastroenterology and Hepatology

fig2

Figure 2

Figure 2: Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma 

Figure 2 | Efficacy and Safety of the Arsenic Trioxide/Lipiodol Emulsion in the Transcatheter Arterial Chemoembolization Combined with Apatinib in the Treatment of Advanced Hepatocellular Carcinoma 